Showing results (121-130 of 177) with videos related to

Sort By:
Pageof 18
Headache|January 9, 2020
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension TrialJessica Ailani, Richard B Lipton, Susan Hutchinson, et al.
European Journal of Pharmacology|June 25, 1991
A68930: a potent agonist selective for the dopamine D1 receptorM P DeNinno, R Schoenleber, R MacKenzie, et al.
Revista Chilena De Infectologia : Organo Oficial De La Sociedad Chilena De Infectologia|October 15, 2021
[Epidemiological characteristics according to the progress of SARS-CoV-2 pandemic in a highly complex pediatric hospital in Argentina: a descriptive study]Daiana Ferraro, Ana Paula Arias, Guadalupe Pérez, et al.
Global Change Biology|May 10, 2019
Climate and plant trait strategies determine tree carbon allocation to leaves and mediate future forest productivityAnna T Trugman, Leander D L Anderegg, Brett T Wolfe, et al.
Annals of Neurology|July 17, 1998
Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutationsY Furukawa, S J Kish, E M Bebin, et al.
Cephalalgia : an International Journal of Headache|January 9, 2023
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trialBrad C Klein, Rosa Miceli, Lawrence Severt, et al.
Annals of Neurology|April 13, 2000
Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I geneY Furukawa, M Guttman, S P Sparagana, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2009
Heavy holes as a precursor to superconductivity in antiferromagnetic CeIn3Suchitra E Sebastian, N Harrison, C D Batista, et al.
Ecology Letters|May 13, 2022
Future climate risks from stress, insects and fire across US forestsWilliam R L Anderegg, Oriana S Chegwidden, Grayson Badgley, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trialsChristopher Gottschalk, Pranav Gandhi, Patricia Pozo-Rosich, et al.
Pageof 18